Express Scripts — Cigna's pharmacy benefit manager — said Thursday that it will expand low-copay access to GLP-1 agonist weight-loss drugs for participants in some of the prescription drug ...

Wegovy and Zepbound — two of three GLP-1 medications currently approved for weight loss in the U.S. — have monthly list prices of $1,349 and $1,060, respectively.

The monthly copay for GLP-1 weight loss medicines will be limited to no more than $200 under the new offering. Patients can save as much as $3,600 per year compared to buying these medications ...

New Evernorth program to cap out-of-pocket costs for Wegovy, Zepbound at $200 By Paige Minemyer May 21, 2025 4:30pm Cigna Evernorth Express Scripts GLP-1 ...

The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit insured customers’ monthly out-of-pocket expenses for weight-loss drugs ...

Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs By Bertha Coombs, CNBC • Published May 21, 2025 • Updated on May 21, 2025 at 6:19 pm ...

Cigna said providing "financial predictability" through a cost cap will allow health plans and employers to better plan to manage GLP-1 spending. That, in turn, would help ensure broader access ...

Cigna reported $1.3 billion in profit for the first quarter of 2025, bucking the ongoing cost trend that dinged other companies in the insurance industry. Its earnings performance surpassed Wall ...

The insurer plans to cap annual price increases for the drugs, called GLP-1 receptor agonists, at 15% for employers and plans participating in a weight loss management program offered by its ...

The GLP-1 drugs are currently only covered by half of The Cigna Group (NYSE:CI)’s clients. Customers who now provide coverage could save as much as 20%.